Featured Research

from universities, journals, and other organizations

Are human genes patentable?

Date:
April 12, 2013
Source:
Washington University in St. Louis
Summary:
On April 15, the Supreme Court of the United States will hear oral argument in Association for Molecular Pathology v. Myriad Genetics, a case that could answer the question, “Under what conditions, if any, are isolated human genes patentable?”. Experts say the layered uncertainties make this case an unusually difficult case in which to predict the outcome.

On April 15, the Supreme Court of the United States will hear oral argument in Association for Molecular Pathology v. Myriad Genetics, a case that could answer the question, "Under what conditions, if any, are isolated human genes patentable?" Kevin Emerson Collins, JD, patent law expert and professor of law at Washington University in St. Louis, believes that layered uncertainties make this case an unusually difficult case in which to predict the outcome.

During the early 1990s, Myriad Genetics made important scientific discoveries related to mutations in the BRCA 1 and BRCA 2 genes, which are biomarkers for increased risk of breast and ovarian cancer. Based on this work, Myriad sought, and obtained, patent protection for "isolated" DNA molecules that embody these sequences.

The Supreme Court's opinion in Myriad will determine whether Myriad's gene patents are valid or, alternatively, whether they were improperly issued from the beginning.

"The legal controversy centers on patent law's 'products of nature' doctrine -- a doctrine that prevents the patenting of newly made products that do not display a 'marked difference' from naturally occurring products," Collins says.

"A perfectly circular section cut out of a leaf of a newly discovered plant may be technically new at the time that it is first made -- and it may be socially useful if the leaf contains chemicals that are natural wound healers, but it's likely an unpatentable product of nature because there is no marked difference between the newly created product and the naturally occurring product.

"Importantly, the Myriad gene patents only encompass DNA molecules in an 'isolated' state, separate from the remainder of the chromosome in which they exist in a human body, and they thus describe molecules that were technically new when Myriad first made them."

The question before the Court is whether the structural and functional differences between naturally occurring DNA molecules and DNA molecules in an isolated state is sufficiently significant to constitute a "marked difference" and to sanction the patenting of the isolated DNAs.

Behind the legal controversy is an economic controversy that may (or may not) influence the Supreme Court's pronouncement on the products of nature doctrine. "The social costs of the exclusive rights to inventions granted by patents are normally justified by the incentives that patents provide for self-interested entities to invest in research and development and generate the socially valuable inventions," Collins says.

However, under some circumstances, there are legitimate concerns that the incentive-based benefits of patents may not outweigh these costs.

"One function of the products of nature doctrine is to ensure that the basic tools of scientific and technological work are not constrained by claims of patent rights and remain free for all to use as inputs into future research," says Collins.

"To the extent that isolated genes are essential technological and scientific building blocks, the costs of Myriad's gene patents in the form of slower innovation in the future may be so great that they will outweigh the benefits of the patent-induced incentives that speed up the creation of the isolated genes themselves."

The verdict

Collins says it is difficult to predict how the Supreme Court will decide this case because of three compounded uncertainties.

First, the Supreme Court has to date not offered a clear legal framework for identifying products of nature, so it is unclear how high a hurdle the markedly different standard will prove to be.

Second, it is unclear how strongly the Court's legal determination will be influenced by the underlying economic concerns about the privatization of the building blocks of technological progress.

Third, the relationship between the Supreme Court and the Federal Circuit Court of Appeals -- the court that authored the opinion below in Myriad -- is not likely to lead to much of any deference.

"Recent Federal Circuit patent decisions have been poorly received by the Supreme Court," Collins says. "The Federal Circuit upheld the patentablity of these genes, but, given recent history, this is not much of an indicator as to Supreme Court will handle this case."


Story Source:

The above story is based on materials provided by Washington University in St. Louis. The original article was written by Jessica Martin. Note: Materials may be edited for content and length.


Cite This Page:

Washington University in St. Louis. "Are human genes patentable?." ScienceDaily. ScienceDaily, 12 April 2013. <www.sciencedaily.com/releases/2013/04/130412084225.htm>.
Washington University in St. Louis. (2013, April 12). Are human genes patentable?. ScienceDaily. Retrieved September 22, 2014 from www.sciencedaily.com/releases/2013/04/130412084225.htm
Washington University in St. Louis. "Are human genes patentable?." ScienceDaily. www.sciencedaily.com/releases/2013/04/130412084225.htm (accessed September 22, 2014).

Share This



More Science & Society News

Monday, September 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Will Climate Rallies Spur Change?

Will Climate Rallies Spur Change?

Newsy (Sep. 21, 2014) Organizers of the People's Climate March and other rallies taking place in 166 countries hope to move U.N. officials to action ahead of their summit. Video provided by Newsy
Powered by NewsLook.com
Global Ebola Aid Increasing But Critics Say It's Late

Global Ebola Aid Increasing But Critics Say It's Late

Newsy (Sep. 21, 2014) More than 100 tons of medical supplies were sent to West Africa on Saturday, but aid workers say the global response is still sluggish. Video provided by Newsy
Powered by NewsLook.com
UN's Ban: Climate Change 'defining Issue of Our Time'

UN's Ban: Climate Change 'defining Issue of Our Time'

Reuters - US Online Video (Sep. 21, 2014) United Nations Secretary-General Ban Ki-moon marches with hundreds of thousands of people in New York for the international day of action on climate change. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
Thousands March in NYC Over Climate Change

Thousands March in NYC Over Climate Change

AP (Sep. 21, 2014) Accompanied by drumbeats, wearing costumes and carrying signs, thousands of demonstrators filled the streets of Manhattan and other cities around the world on Sunday to urge policy makers to take action on climate change. (Sept. 21) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins